cost of degarelix
Compared with triptorelin and an antiandrogen, degarelix was associated with an incremental cost of Â£59,012 per QALY gained. The probabilistic sensitivity analysis showed that at a willingness-to-pay threshold of Â£30,000 per additional QALY gained, degarelix was cost-effective in less than 10% of simulations.